Vall d'Hebron Institute of Oncology (VHIO)
Josep Villanueva began their work experience in 2000 as a Postdoc at the Universitat Autònoma de Barcelona. Josep then transitioned to the Memorial Sloan-Kettering Cancer Center where they held several roles, including Research Fellow, Research Associate, and eventually Senior Research Scientist. In 2009, they became the Head of the Tumor Biomarkers Laboratory at VALL D'HEBRON INSTITUT D'ONCOLOGIA.
Josep Villanueva has an education history that includes a PhD program in Biochemistry and Molecular Biology at Universitat Autònoma de Barcelona from 1995 to 2000. Prior to that, they studied Biochemistry at the same university from 1989 to 1995. Josep'ssecondary education was completed at Institut Margarida Xirgu, where they earned a Batxillerat degree from 1985 to 1989.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.